Subjects voluntarily participate in the study and sign the informed consent form;
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
Expected survival time ≥ 3 months;
Histologically or cytologically confirmed diagnosis of pancreatic cancer;
No prior systemic anti-tumor treatment for unresectable locally advanced or metastatic disease;
At least one measurable lesion per RECIST v1.1;
Patients with adequate cardiac, liver, renal function, etc.
You may not be if
History of malignancies other than the target cancer within 5 years prior to the first dose of the investigational product ;
Underwent major organ surgery (excluding needle biopsy) or had significant trauma within 28 days prior to enrollment, or requires elective surgery during the study;
Known central nervous system metastases;
Patients with hepatitis B; patients with hepatitis C; patients who test positive for syphilis, or patients with a known history of HIV or positive HIV screening test;
Patients with added risks associated with the study or may interfere with the interpretation of study results as determined by the investigator, or deemed unsuitable by the investigator.
